PRAXIS PRECISION MEDICINES PRAX 深 沪
等待开盘 12-08 09:30:00 美东时间
247.99
+58.020
+30.54%
华盛通- 最 高277.44
- 今 开241.00
- 成交量 289.40万股
- 最 低 240.41
- 昨 收 189.97
- 总市值 52.20亿
- 52周最高 277.44
- 市盈率 静 --
- 换手率 13.75%
- 52周最低 26.70
- 委 比 -15.18%
- 总股本 2104.96万
- 历史最高 914.265
- 量 比 3.20
- 振 幅 19.49%
- 历史最低 11.85
- 每 手 1
- 风险率 47.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | SMX 隔夜飙涨135.4%，DigitalBridge隔夜大涨45.3%
SMX (Security Matters) Public Ltd Co Ordinary Shares - Class A涨135.4%；DigitalBridge Group涨45.3%；Toro Corp. - Common stock涨40.4%
12-06 08:28
Praxis' Epilepsy Drug Too Good To Continue, FDA Meeting Up Next
Praxis Precision stock rallies on positive EMBOLD results, FDA meeting confirmed, and analyst increases probability of success and peak sales.
12-06 02:10
Market-Moving News for December 5th
PRAX: 30% | Praxis Precision Medicines shares are trading higher after the company announced the completion of its pre-NDA meeting with the FDA and it gained alignment from the agency. The company announced results
12-05 20:24
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Akanda (NASDAQ:AKAN) stock rose 28.9% to $1.22 during Friday's pre-mar...
12-05 20:05
美股盘后 | PRAXIS PRECISION MEDICINES涨15.97%
PRAXIS公司EMBOLD研究因疗效提前终止，将在癫痫学会分享结果；FDA将审查数据讨论后续计划。其创新药物relutrigine已获多项监管认定，研究显示对运动性癫痫发作有显著改善效果。
12-05 06:23
Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies
Praxis Precision Medicines announced positive results from the EMBOLD study of relutrigine for treating SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs), leading to early trial termination for efficacy. The data will be presented at the American Epilepsy Society Annual Meeting on December 6, 2025, and Praxis plans to meet with the FDA to discuss the findings and potential NDA filing. Relutrigine is a first-in-class therapy targ...
12-04 21:10
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Boston Dec. 03 2025. Praxis Precision Medicines granted 3594 restricted stock units to six new non-executive employees under the 2024 Inducement Plan. These awards vest over four years contingent on continued employment and were granted as an inducement to join Praxis. The 2024 Inducement Plan is exclusively for attracting new employees. Praxis specializes in developing therapies for CNS disorders using genetic insights.
12-03 21:01
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
12-02 09:50
Needham Reiterates Buy on Praxis Precision Medicine, Maintains $250 Price Target
Needham analyst Ami Fadia reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $250 price target.
12-01 18:37
